NovoCure (NVCR) Total Liabilities (2014 - 2026)

NovoCure has disclosed Total Liabilities across 13 years of filings, most recently posting $457.2 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $457.2 million, down 48.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $457.2 million (down 48.45% YoY), and the FY2025 annual result was $463.9 million, down 47.32% from the prior year.
• Total Liabilities came in at $457.2 million for Q1 2026 at NovoCure, down from $463.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.0 billion in Q3 2025 to a low of $457.2 million in Q1 2026.
• The 5-year median for Total Liabilities is $752.6 million (2023), against an average of $765.6 million.
• Across the five-year window, Total Liabilities gained 18.42% in 2025 and sank 48.45% in 2026, its largest moves.
• NovoCure's Total Liabilities stood at $750.5 million in 2022, then advanced by 4.42% to $783.6 million in 2023, then advanced by 12.37% to $880.6 million in 2024, then plunged by 47.32% to $463.9 million in 2025, then fell by 1.43% to $457.2 million in 2026.
• The last three Total Liabilities figures came in at $457.2 million (Q1 2026), $463.9 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.